Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 2, 2014Breast Cancer ResearchOpen Access

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYun ShiTongliao Academy of Agricultural SciencesXFXuejun FanThe University of Texas Health Science Center at HoustonWMWeixu MengNanjing Tech University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shi et al. (2014) studied this question.

synapsesocial.com/papers/6a0f3cd204e2b0ba896cb955https://doi.org/10.1186/bcr3637
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy2011 · 499 citations
  2. 2Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin2004 · 497 citations